NCT03462511View on ClinicalTrials.gov

Hydroxyurea Adherence for Personal Best in Sickle Cell Disease (HABIT): Efficacy Trial

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 15, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Sickle Cell Disease
Interventions
BEHAVIORAL

HABIT Intervention

Dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.

OTHER

Standard of Care

Standard of care used to treat patients with SCD

OTHER

Education materials

Education materials provided to all patients enrolled in the trial

Trial Locations (4)

10032

Columbia University Irving Medical Center, New York

10461

Albert Einstein College of Medicine, The Bronx

11030

Feinstein Institute for Medical Research, Manhasset

19104

The Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
lead

Columbia University

OTHER

collaborator

National Institute of Nursing Research (NINR)

NIH

NCT03462511 - Hydroxyurea Adherence for Personal Best in Sickle Cell Disease (HABIT): Efficacy Trial | Biotech Hunter | Biotech Hunter